GeneArrest Ltd is developing a new platform for drug discovery based on designed chemicals that are targeting dsDNA with high specificity & selectivity. This technology makes it possible to treat disease and improve the lives of patients in a fundamentally new way by silencing disease-causing genes upstream of today’s medicines. SNNLive spoke to GeneArrest’s CEO, Dr. Anwar Rayan, at the 2012 BioInvest Israel Conference in Haifa.
Dr. Rayan is a research associate at the Hebrew university of Jerusalem and a researcher at the Qasemi Research Center at Alkasemi College. Dr. Rayan has gained vast experience in the field ofdrug discovery and algorithm development while working at the School of Pharmacy at the Hebrew University in Jerusalem and at FMP in Berlin. In this interview, he discusses GeneArrest’s work developing new technology for targeting genes in order to treat HIV. “We think that we are the first company to treat HIV-1 infect[ed] people in the latent stage before symptoms of AIDS start to appear.” To learn more about GeneArrest, visit them at their website. SNNLive welcomes Dr. Anwar Rayan, CEO of GeneArrest.
Micro-Cap Review Latest Issue
Cavaet Emptor or Buyer Beware by SNN Inc. CEO Sheldon “Shelly” Kraft
Check out the book "Caveat Emptor" written by CEO Sheldon Kraft, click on the image to view a preview and the full book can be purchased for $15.95.
There are some best practices and good hints on what to look out for in today’s volatile markets.